GSK hepatitis C shot shows promise, bodes well for Ebola vaccines

By Kate Kelland LONDON (Reuters) - A new hepatitis C vaccine from GlaxoSmithKline based on the same technology as an experimental Ebola shot being fast-tracked through human trials has shown promise in early clinical tests, prompting strong and broad immune responses. Researchers testing the vaccine -- the first hepatitis C vaccine to reach second stage clinical trials -- said their results in a group of 15 healthy human volunteers showed it was very safe and well tolerated, and generated immune responses of a strength never seen before in a vaccine against this disease. ...



via Health News Headlines - Yahoo News http://ift.tt/1tISR7k